Renalytix launches formal sale process after unsolicited approach from strategic diagnostic firm

Renalytix plc

Unsolicited approach from a large, publicly listed diagnostics company evaluating acquisition of all shares.
Formal sale process launched; Stifel appointed as Sole Financial Adviser and Rule 3 Adviser.
Advanced financing discussions with existing shareholders and potential new equity/debt providers underway.
Cash on hand $2.3M plus $1.4M marketable securities as of March 3; expects cash to fund through April 2024.
No certainty any offer will be made; Board may pursue alternative strategic options including staying independent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.